Sage Journals: Discover world-class research

Abstract

Introduction

Early-onset colorectal cancer (EOCRC) patients are more likely to have advanced diagnoses across different race/ethnicity or age at diagnosis groups. Thus, we examined the relationship of racial/ethnic disparities with cancer diagnoses (tumor features and histologic types) and 5-year causes-specific survival for EOCRC across three age-at-diagnosis groups.

Methods

We conducted a retrospective cohort analysis using the 2006-2020 Surveillance, Epidemiology, and End Results (SEER) Program, using multivariable logistic and Cox proportional hazards models to examine the association of race/ethnicity and age with survival.

Results

Among 46,956 EOCRC patients, racial minorities were diagnosed with EOCRC at age of 20-29 years while non-Hispanic White patients were more commonly diagnosed at age 40-49 years (P-value <0.001). In adjusted analysis, non-Hispanic Black (NHB) (AOR, 1.65; 95% CI, 1.24-2.18), Asian/Pacific Islander (AOR, 2.22; 95% CI, 1.60-3.08), and Hispanic (AOR, 1.56; 95% CI, 1.27-1.93) patients aged 20-29 years were more likely to be diagnosed at a late stage. These groups were also more likely to have mucinous adenocarcinoma or signet ring cell subtypes (NHB: AOR,1.46; 95% CI, 1.00-2.13; Asian/PI: AOR, 1.89; 95% CI, 1.28-2.77; Hispanic: AOR, 1.95: 95% CI, 1.48-2.59). Regardless of age groups, NHB patients were more likely to die from CRC by 34%-59% (20-29 years: AHR, 1.40; 95% CI, 1.11-1.76; 30-39 years: AHR, 1.59; 95% CI, 1.42-1.77; 40-49 years: AHR, 1.34; 95% CI, 1.26-1.41).

Conclusion

Prioritizing prevention strategies and enhancing access to screening for racial minorities and the 20-29 age group is warranted.

Keywords

young adults colorectal cancer race/ethnicity age at diagnosis SEER

Introduction

The incidence of early-onset CRC (EOCRC, defined as diagnosed with CRC at age 18-49 years) has been increasing rapidly in the United States.¹ EOCRC incidence among adults aged 20-34 years is predicted to increase by 90% by 2030.² EOCRC mortality rates have also increased by 1.3% per year from 2008 to 2017.³ This is particularly concerning because young individuals are currently below the recommended age for screening and may experience limited access to preventive care. Although the contributing factors to these trends of EOCRC are still unclear, prior research has identified different clinical presentations and sociodemographic characteristics between EOCRC and average-onset CRC (defined as diagnosed with CRC at age 50+). For example, EOCRC patients are more likely to present with poorly differentiated tumors and be diagnosed at a later stage compared to older patients (50+ years).⁴ This is largely attributed to delayed diagnosis and a lack of awareness or underestimation of risk by healthcare providers.⁵ There is also higher prevalence of signet ring carcinomas (SC) and mucinous adenocarcinomas (MAC) among young populations compared to older groups.^6,7 Some racial minorities (eg, American Indian/Alaskan Native, Black, or Asian) are also more likely than Whites to have greater risk of CRC mortality or the mentioned advanced diagnoses including right-sided CRC.^8,9

Further, younger patients under 40 years, particularly those aged 20-29 years, have higher rates of high pathological grading, late-stage diagnosis, and a greater prevalence of SC and MAC.⁴ However, these analyses have not been jointly examined clinical features and survival by race/ethnicity and age. Research on EOCRC survival across age groups is also limited. Such integrated information is important for guiding preventive strategies aimed at screening efficiency and treatment approaches for EOCRC. Therefore, we examined the relationship of racial/ethnic differences with tumor features and histologic types as well as 5-year causes-specific survival for EOCRC while considering the role of age at diagnosis. We hypothesize that racial/ethnic differences in EOCRC are linked to variations in tumor features, histologic types, and 5-year survival, with age at diagnosis as a moderating role.

Methods

We conducted a retrospective cohort analysis using the 2006-2020 Incidence Data with Census Tract Attributes from Surveillance, Epidemiology, and End Results (SEER) Program (22 registries, Nov 2022 submission, https://seer.cancer.gov/) (n = 835,907). We excluded 11,338 patients due to duplicate records and 730,531 patients diagnosed with CRC at age 50 or older. To ensure a more homogeneous sample, we further excluded 47,082 EOCRC patients based on several criteria, including patients diagnosed after 2015 (n = 34,530) due to limited follow-up time, and those with missing data on rurality (n = 5), persistent poverty (n = 28), survival time (n = 183), vital status (n = 1), race (n = 407), surgery (n = 684), stage (n = 2537), pathological grading (n = 8702), or primary site (n = 5). After these exclusions, 46,956 eligible EOCRC patients remained for our analysis.

Tumor features (late stage at diagnosis, high pathological grading, right-sided CRC), histologic types (SC, MAC), and 5-year CRC survival (deaths from other causes censored) were outcomes of interest. We classified high pathological grade as “yes” if tumors were poorly differentiated or undifferentiated, and “no” for all other grades. Stage at diagnosis was defined using SEER summary staging, with regional and distant stages considered late-stage disease (“yes”) and all other stages as “no”. Tumor location was categorized as right-sided (cecum to transverse colon; codes C18.0–C18.4) or left-sided (splenic flexure to rectum; codes C18.5–C18.9, C19.9, C20.9). Histologic types included MAC and SC; these were grouped as MAC/SC (yes or no). Survival time was calculated in months from the date of diagnosis up to 60 months, with follow-up censored on December 31, 2020, or at the time of death from non-CRC causes.

Exposures of interest included age at diagnosis (defined by 10-year ranges within the definition of EOCRC, ie, 20-29, 30-39, 40-49 years) and race/ethnicity (non-Hispanic White [NHW], non-Hispanic Black [NHB], Asian /Pacific Islanders [PI], American Indian/Alaskan Native [AI/AN]). Covariates of interest include sex (male or female), marital status at diagnosis (married or unmarried), census-tract level rurality (yes or no), persistent poverty (yes or no), CRC constitutes first cancer diagnosis in a patient’s lifetime (yes or no), diagnosis year (2006-2010 or 2011-2015), and treatment (surgery, chemotherapy, radiation; yes or no).

Statistical Analysis

Descriptive statistics were used to summarize the distribution of EOCRC patients by race/ethnicity and across three age groups. Frequencies and percentages were reported. Bivariate analyses using chi-square tests were conducted to examine the association between race/ethnicity and age groups. Multivariable logistic regression models were performed to examine racial differences in tumor features and histologic types across three age groups. Further, Cox proportional hazards models were conducted to evaluate the association between race/ethnicity and EOCRC survival by age groups. To address potential bias confounders, logistic regression models were adjusted for all covariates of interest while Cox proportional hazards models were adjusted for all covariates of interest, tumor features, and histologic types. Data were analyzed using SAS version 9.4. Statistical significance was a 2-sided P-value <0.05. Data extracted for this study were publicly available and de-identified and thus considered exempt from the institutional review board at Augusta University. The reporting of this study conforms to RECORD guidelines.¹⁰

Results

Among 46,956 EOCRC eligible patients, a majority of EOCRC patients were NHW (57.7%) followed, in decreasing frequency, by Hispanic, NHB, Asian/PI, and AI/AN (overall mean survival time was 47.8 months with SD = 19.3). A higher percentage of AI/AN, Asian/PI, and Hispanic patients were diagnosed with CRC at the age of 20-29 years compared to NHW and NHB patients. Conversely, more EOCRC NHW and NHB patients were diagnosed at age 40-49 years compared to other racial groups (P-value <0.001) (Table 1).

Table 1.

Distribution of Race/Ethnicity Across Three Age Groups (n = 46,956)

	Total (n = 46,956)	20-29 years (n = 2,504, 5.3%)	30-39 years (n = 9,735,20.7%)	40-49 years (n = 34,717,73.9%)	P-value
	n (%)
Race					<0.001
NHW	27,071 (57.7%)	1347 (5.0%)	5336 (19.7%)	20,388 (75.3%)
NHB	6505 (13.9%)	290 (4.5%)	1225 (18.8%)	4990 (76.7%)
AI/AN^a	287 (0.6%)	20 (7.0%)	62 (21.6%)	205 (71.4%)
Asian/PI	3979 (8.5%)	224 (5.6%)	826 (20.8%)	2929 (73.6%)
Hispanic	9114 (19.4%)	623 (6.8%)	2286 (25.1%)	6205 (68.1%)

Abbreviations: NHW, non-Hispanic White; NHB, non-Hispanic Black; AI/AN, American Indian/Alaskan Native; PI, Pacific Islanders.

Notes: Missing data from all variables were excluded based on our prior work. Details of sample selection were provided in the method section. (Reference: Tsai MH, Shahsavari D, Chen J, Moazzami B, Sridhar S. Racial/Ethnic Disparities in Early-Onset Colorectal Cancer Outcomes. J Racial Ethn Health Disparities. 2025 Apr 26. doi: 10.1007/s40615-025-02450-5. Epub ahead of print. PMID: 40287583).

In adjusted analysis, NHB (adjusted OR (AOR), 1.65; 95% CI, 1.24-2.18), Asian/PI (AOR, 2.22; 95%CI, 1.60-3.08), and Hispanic (AOR, 1.56; 95% CI, 1.27-1.93) patients aged 20-29 years were more likely to have late stage at diagnosis than NHW patients (Table 2). Similarly, those racial minorities who were aged 20-29 years were also 1.46-1.95 times more likely to be diagnosed with MAC/SC subtypes (NHB: AOR, 1.46; 95% CI, 1.00-2.13; Asian/PI: AOR, 1.89; 95% CI, 1.28-2.77; Hispanic: AOR, 1.95: 95% CI, 1.48-2.59) (Table 3). Further, NHB patients aged 40-49 years (AOR, 1.61; 95%CI, 1.51-1.73) and Asian/PI patients aged 20-29 years (AOR, 2.16; 95%CI, 1.59-2.92) demonstrated higher estimates on diagnoses of right-sided CRC and high pathological grading tumor, respectively (Table 2). Regardless of age, NHB EOCRC patients had a 34%-59% higher risk of CRC death (20-29 years: AHR, 1.40; 95% CI, 1.11-1.76; 30-39 years: AHR, 1.59; 95% CI, 1.42-1.77; 40-49 years: AHR, 1.34; 95% CI, 1.26-1.41) (Table 3). Finally, we found no significant interactions of race/ethnicity and other covariates of interest across three age groups.

Table 2.

Association Between Race/Ethnicity and Tumor Features by Three Age Groups (n = 46,956)

	Late-stage diagnosis^a			Right-sided CRC^a			High-grade CRC^a
	20-29 years (n = 2,504,5.3%)	30-39 years (n = 9,735,20.7%)	40-49 years (n = 34,717,73.9%)	20-29 years (n = 2,504,5.3%)	30-39 years (n = 9,735,20.7%)	40-49 years (n = 34,717,73.9%)	20-29 years (n = 2,504,5.3%)	30-39 years (n = 9,735,20.7%)	40-49 years (n = 34,717,73.9%)
	OR (95%CI)
NHW	Reference	Reference	Reference	Reference	Reference	Reference	Reference	Reference	Reference
NHB	1.65 (1.24, 2.18)	1.07 (0.93,1.24)	1.07 (1.00,1.15)	0.75 (0.57,0.99)	1.46 (1.28,1.67)	1.61 (1.51,1.73)	1.27 (0.95,1.71)	0.95 (0.81,1.10)	0.81 (0.74,0.88)
AI/AN	1.02 (0.41,2.59)	0.71 (0.42,1.20)	1.12 (0.83,1.52)	1.24 (0.49,3.11)	1.01 (0.59,1.75)	0.82 (0.59,1.13)	2.19 (0.87,5.50)	0.93 (0.51,1.71)	0.84 (0.59,1.20)
Asian/PI	2.22 (1.60,3.08)	1.03 (0.87,1.21)	1.09 (1.00,1.19)	0.73 (0.54,0.99)	0.85 (0.72,1.00)	0.75 (0.69,0.83)	2.16 (1.59,2.92)	1.46 (1.24,1.72)	1.01 (0.91,1.11)
Hispanic	1.56 (1.27,1.93)	1.07 (0.96,1.20)	1.08 (1.01,1.15)	0.84 (0.68,1.03)	1.05 (0.94,1.17)	1.02 (0.95,1.08)	1.44 (1.15,1.80)	0.97 (0.81,1.10)	0.90 (0.74,0.88)

Abbreviations: CRC, colorectal cancer; OR, odd ratio; HR, hazard ratio; NHW, non-Hispanic White; NHB, non-Hispanic Black; AI/AN, American Indian/Alaskan Native; PI, Pacific Islanders; CI, confidence interval.

Italicized text indicates statistically significant results.

^aModels were adjusted for patient demographics (marital status, census-tract level rurality, census-tract level persistent poverty), year of diagnosis, and first malignant primary cancer.

Notes: Three models were presented. Covariates of interest (not shown in the table) were selected based on prior literature and their potential to act as confounders.

Table 3.

Association Between Race/Ethnicity and Histologic Types and Causes-specific Survival by Three Age Groups (n = 46,956)

	MAC/SC^a			Risk of EOCRC death^b
	20-29 years (n = 2,504,5.3%)	30-39 years (n = 9,735,20.7%)	40-49 years (n = 34,717,73.9%)	20-29 years (n = 2,504,5.3%)	30-39 years (n = 9,735,20.7%)	40-49 years (n = 34,717,73.9%)
	OR (95% CI)			HR (95% CI)
NHW	Reference	Reference	Reference	Reference	Reference	Reference
NHB	1.46 (1.00,2.13)	1.07 (0.88,1.31)	1.00 (0.89,1.12)	1.40 (1.11,1.76)	1.59 (1.42,1.77)	1.34 (1.26,1.41)
AI/AN	1.48 (0.42,5.22)	0.70 (0.28,1.76)	0.84 (0.50,1.41)	1.38 (0.56,3.40)	1.00 (0.61,1.65)	1.07 (0.84,1.37)
Asian/PI	1.89 (1.28,2.77)	1.15 (0.92,1.45)	1.01 (0.89,1.16)	1.12 (0.87,1.46)	1.07 (0.93,1.23)	1.04 (0.97,1.12)
Hispanic	1.95 (1.48,2.59)	1.27 (1.09,1.47)	1.18 (1.08,1.30)	1.08 (0.90,1.31)	1.15 (1.05,1.27)	1.08 (1.02,1.14)

Abbreviations: EOCRC, early-onset colorectal cancer; OR, odd ratio; HR, hazard ratio; NHW, non-Hispanic White; NHB, non-Hispanic Black; AI/AN, American Indian/Alaskan Native; PI, Pacific Islanders; MAC/SC, mucinous adenocarcinomas/ signet ring; CI, confidence interval.

Italicized text indicates statistically significant results.

^aModels were adjusted for patient demographics (marital status, census-tract level rurality, census-tract level persistent poverty), year of diagnosis, and first malignant primary cancer.

^bModels were adjusted for patient demographics (marital status, census-tract level rurality, census-tract level persistent poverty), year of diagnosis, first malignant primary cancer, tumor features (late stage at diagnosis, high pathological grade, primary site), histologic types (adenocarcinoma, mucinous adenocarcinoma/signet-ring cell carcinoma), and treatment initiation (surgery, radiation, chemotherapy).

Notes: Two models were presented. Covariates of interest (not shown in the table) were selected based on prior literature and their potential to act as confounders.

Discussion

This is the first study to examine integrated relationships of race/ethnicity and age at diagnosis with various clinical features and mortality for EOCRC by using a representative US sample. Our findings indicate NHB, Asian/PI, and Hispanic patients aged 20-29 years were more likely to have advanced diagnoses, including late stage at diagnosis, MAC/SC subtypes, and/or high pathological grading. No prior research has examined race/ethnicity and age groups together, making direct comparisons difficult. However, these clinical presentations are generally linked to poor EOCRC prognosis.⁴ Our analysis confirms that NHB patients are more likely to die from EOCRC,⁹ with the highest estimate observed among those aged 30-39 years. It is possible that younger racial minorities with advanced EOCRC diagnosis or death have lower awareness of CRC or lack access to healthcare that leads to a delayed diagnosis.⁵ One modifiable factor that could improve CRC outcomes is CRC screening because it can detect tumors at earlier stages and remove pre-cancerous polyps¹¹; however, younger populations often fall below the recommended screening age and may face additional barriers to accessing care, limiting early detection opportunities.

Our findings highlight disparities in clinical outcomes among adults aged 20-29 and racial minorities (NHB, Asian/Pacific Islander, and Hispanic individuals), underscoring the need for targeted, tailored prevention strategies. Young adults, particularly from racial minority groups, often face barriers such as limited access to care and low cancer risk awareness, contributing to delayed and advanced diagnoses.⁵ This is especially relevant for racial minorities, where the complex interplay between race/ethnicity and social determinants of health—such as access to care, socioeconomic status, and structural barriers—may further impact cancer outcomes.¹ Therefore, culturally tailored patient-provider communication about CRC risk is especially important for these racial minorities aged 20-29. Screening recommendations that specifically address this age group and these populations may improve the effectiveness of prevention strategies.⁸ Additionally, increased investment in CRC education programs is also essential to improve risk awareness among these young racial minorities. An important limitation is that several important factors (eg, the family history of CRC) associated with advanced diagnoses and mortality are unavailable in cancer registries. Future research should explore additional clinical factors (eg, biomarkers) linked to EOCRC diagnoses in young racial minorities to help reduce outcome disparities.

Conclusion

Racial minorities aged 20-29 are more likely to have advanced diagnoses, and NHB patients faced higher EOCRC mortality across all ages. These findings emphasize the need for earlier CRC risk assessment and improved access to care for young racial minorities, supported by targeted education and navigation programs to raise awareness and enhance preventive care.

Footnotes

ORCID iDs

Meng-Han Tsai

Kenneth J. Vega

Ethical Approval

This research does not involve human and/or animal experimentation by any of the authors. Data extracted for this study was publicly available and de-identified, and thus considered exempt from IRB review at Augusta University.

Author Contributions

Dr Tsai had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Tsai.Acquisition, analysis, or interpretation of data: Tsai, Cortes, Vega. Drafting of the manuscript: Tsai, Cortes, Vega. Critical revision of the manuscript for important intellectual content: Tsai, Cortes, Vega. Statistical analysis: Tsai. Obtained funding: Tsai. Administrative, technical, or material support: Cortes, Vega. Supervision: Cortes.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Dr Tsai was supported at least in part through the Georgia Cancer Center Paceline funding mechanism at Augusta University (MCGFD01071) and National Cancer Institute (NCI, R21CA301113). The content is solely the responsibility of the authors and does not necessarily represent the official views of Augusta University and NCI.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Data Availability Statement

The datasets generated during the current study are available in the Surveillance, Epidemiology, and End Results Program () repository.

Appendix

References

Siegel

Wagle

Cercek

Smith

Jemal

. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73(3):233-254. doi:10.3322/caac.21772

Bailey

You

, et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg. 2015;150(1):17-22. doi:10.1001/jamasurg.2014.1756

Burnett-Hartman

Lee

Demb

Gupta

. An update on the epidemiology, molecular characterization, diagnosis, and screening strategies for early-onset colorectal cancer. Gastroenterology. 2021;160(4):1041-1049. doi:10.1053/j.gastro.2020.12.068

Yeo

Betel

Abelson

Zheng

Yantiss

Shah

. Early-onset colorectal cancer is distinct from traditional colorectal cancer. Clin Colorectal Cancer. 2017;16(4):293-299. doi:10.1016/j.clcc.2017.06.002

Adigun

Adebile

Okoye

, et al. Causes and prevention of early-onset colorectal cancer. Cureus. 2023;15(9):e45095. doi:10.7759/cureus.45095

Perotti

Fabiano

Contiero

, et al. Influence of sex and age on site of onset, morphology, and site of metastasis in colorectal cancer: a population-based study on data from four Italian cancer registries. Cancers. 2023;15(3):803. doi:10.3390/cancers15030803

Willauer

Liu

Pereira

AAL

, et al. Clinical and molecular characterization of early-onset colorectal cancer. Cancer. 2019;125(12):2002-2010. doi:10.1002/cncr.31994

Petrick

Barber

Andersen

Florio

Palmer

Rosenberg

. Racial disparities and sex differences in early- and late-onset colorectal cancer incidence, 2001-2018. Front Oncol. 2021;11:734998. doi:10.3389/fonc.2021.734998

Tsai

Shahsavari

Chen

Moazzami

Sridhar

. Racial/Ethnic disparities in early-onset colorectal cancer outcomes. J Racial Ethn Health Dispar 2025 Apr 26. doi:10.1007/s40615-025-02450-5. Epub ahead of print. PMID: 40287583.

10.

Benchimol

Smeeth

Guttmann

, et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLoS Med. 2015;12(10):e1001885. doi:10.1371/journal.pmed.1001885

11.

Jacobs

Zhu

Luo

, et al. Defining early-onset colon and rectal cancers. Front Oncol. 2018;8:504. doi:10.3389/fonc.2018.00504

Racial/Ethnic and Age-Related Disparities in Early-Onset Colorectal Cancer Diagnoses and Survival

Abstract

Introduction

Methods

Results

Conclusion

Keywords

Introduction

Methods

Statistical Analysis

Results

Discussion

Conclusion

Footnotes

ORCID iDs

Ethical Approval

Author Contributions

Funding

Declaration of Conflicting Interests

Data Availability Statement

Appendix

References